CTRI/2008/091/000309尚未招募3 期
A prospective, single arm, open trial to assess the safety and efficacy of Fondaparinux in patients with unstable angina and non-ST elevation myocardial infarction compared to historical controls treated with Enoxaparin.
Christian Medical College, Vellore0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients will be eligible if they meet at least 1 of the 3 following criteria:
- •1. Unstable angina as defined as angina pectoris or equivalent type of ischemic discomfort with at least one of 3 features:
- •a) Occurring at rest or with minimal exertion and usually lasting more than 20 min.
- •b) Being severe and frank pain and of new onset
- •c) Occurring with a crescendo pattern
- •2. An elevated level of troponin or creatine kinase MB
- •3. ECG changes indicative of ischemia.
排除标准
- •1. Contraindications to anticoagulation
- •2. Recent hemorrhagic stroke
- •3. Indications for anticoagulation other than an acute coronary syndrome
- •4. Serum creatinine level >3 mg/dl.
- •5. Severe hepatic failure
- •6. Any active major bleeding.
研究者
相似试验
进行中（未招募）
不适用
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)EUCTR2008-004007-64-DEGlaxoSmithKline Biologicals115
进行中（未招募）
1 期
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaEUCTR2008-004007-64-FIGlaxoSmithKline Biologicals125
进行中（未招募）
不适用
A study to test the benefit of a new anti-cancer Treatment in patients with unresectable advanced melanomaFirst-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanomaMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-004007-64-ITGlaxoSmithKline Biologicals115
进行中（未招募）
不适用
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaEUCTR2008-004007-64-IEGlaxoSmithKline Biologicals115
进行中（未招募）
1 期
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)EUCTR2008-004007-64-FRGlaxoSmithKline Biologicals125